Lewis Cantley
PhD
Director, Sandra and Edward Meyer Cancer Center
👥Biography 个人简介
Lewis Cantley at Weill Cornell Medicine discovered the PI3K enzyme in 1984, laying the groundwork for one of oncology's most important signaling pathways and drug target families. His foundational work on phosphoinositide 3-kinase led directly to the development of alpelisib, the first PI3Ka-specific inhibitor approved for PIK3CA-mutated breast cancer. He continues to study PI3K pathway biology and rational drug combination strategies to overcome resistance. He has been recognized with the Breakthrough Prize in Life Sciences for his contributions to cancer biology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Lewis Cantley 的研究动态
Follow Lewis Cantley's research updates
留下邮箱，当我们发布与 Lewis Cantley（Weill Cornell Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment